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Abstract	
	
Clustered	 regularly	 interspaced	 short	 palindromic	 repeats	 (CRISPR)	 is	 a	 precise	 genetic	
engineering	 tool	 for	 genome	 editing.	 CRISPR	 utilizes	 guide	 RNA	 (gRNA)	 to	 find	 specific	 DNA	
sequences	 followed	by	 a	 Cas9	 nuclease	 to	 cut	 the	DNA	at	 a	 specific	 site.	 	 TRM9L	 is	 a	 tumor	
growth-suppresser	gene	that	restricts	the	growth	of	some	colorectal	cancer	cells	by	upregulating	
LIN9	 expression.	 TRM9L	 expression	 is	 lost	 in	 some	 late	 stage	 colorectal	 cancers	 and	 cancer	
models	(SW620).	SW480	colorectal	cancer	cells	express	TRM9L	and	these	cells	are	considered	to	
be	at	the	beginning	of	colorectal	cancer	development.		The	goal	of	my	project	was	to	use	genetic	
engineering	approaches	to	remove	TRM9L	from	early	stage	colorectal	cancer	cells	(SW480)	and	
to	 then	 determine	 the	 effect	 on	 tumor	 growth.	 	 In	 this	 project,	 CRISPR	 constructs	 were	
synthesized,	hybridized,	and	ligated	to	an	expression	vector.		The	hybridized	vector	underwent	
bacterial-facilitated	 replication	and	was	 then	harvested	via	plasmid	purification.	The	plasmids	
were	gene	sequenced	and	then	transfected	into	a	growing	culture	of	SW480	cells.	After	a	month	
of	plasmid-inclusion	growth,	 the	 cell	 cultures	will	 be	analyzed	 for	 growth	effects.	My	work	 is	
important	because	it	will	develop	new	tools	for	use	in	colorectal	cancer	research,	a	disease	that	
claims	over	50,000	lives	each	year.	
	
	 	
3	
	
Acknowledgements	
	
I	would	like	to	thank	my	advisor,	Dr.	Thomas	Begley,	for	never	giving	up	hope	on	me	regardless	
of	the	situation.	
I	would	also	like	to	thank	Uli	Begley	and	Khadijah	Onanuga	for	their	mentorship	and	guidance	
throughout	the	entirety	of	the	project.	This	study	would	not	have	any	substantiability	if	it	were	
not	for	them.	
	 	
4	
	
Table	of	Contents	
	
Abstract	…………………………………………………………………………………………………………………………………….2	
Acknowledgments	…………………………………………………………………………………………………………………….3	
Background	……………………………………………………………………………………………………………………………….5	
Materials	and	Methods	…………………………………………………………………………………………………………..11	
Results	…………………………………………………………………………………………………………………………………….20	
Discussion………………………………………………………………………………………………………………………………..23	
Pitfalls	and	Limitations	…………………………………………………………………………………………………………….24	
Current	Work	in	the	Field	….…………………………………………………………………………………………………….25	
Conclusions	….…………………………………………………………………………………………………………………………29	
Future	Plans	……………………………………………………………………………………………………………………………29	
References	..…………………………………………………………………………………………………………………………….31
5	
	
Background	
Yeast	Trm9	is	a	tRNA	methyltransferase	enzyme	that	modifies	the	wobble	uridine	and	
helps	prevent	damage-induced	cell	death1.	Trm9	catalyzes	the	modification	of	wobble	bases	in	
specific	tRNA	anticodons,	and	promotes	increased	levels	of	important	damage-response	
proteins2.		The	TRM9	gene	was	first	identified	in	2003	when	researchers	showed	the	deletion	of	
the	F6	gene	(later	called	TRM9)	lead	to	hypomethyl	esterification	of	specific	tRNA	bases2.	The	
human	tRNA	methyltransferase	9-like	(hTRM9L)	protein	is	a	homolog	of	yeast	Trm9.	TRM9L	is	a	
tumor	growth	suppressor	that	acts	as	control	for	LIN9	expression	by	influencing	the	translation	
of	specific	proteins	involved	in	the	regulation	of	LIN9.		It	was	discovered	when	researchers	
studying	hTRM9L	expression	in	SW620	(colorectal	cancer)	cells	achieved	a	93%	knockdown	of	
LIN9	in	the	cells	and	then	consequently	observed	a	reversal	of	the	hTMR9L	tumor	growth	
suppression	phenotype	in	the	SW620	expressing	cells3.	
	
Figure	1.	hTRM9L’s	role	in	a	cellular	stress	response	by	increasing	LIN9	expression.	
Image	retrieved	from	reference	(3)		
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The	TRM9L	protein	affects	a	cell’s	ability	to	restrict	cancer	growth,	as	TRM9L	deficient	
cells	have	been	shown	to	proliferate	while	TRM9L	proficient	cells	are	in	a	cell-replication	arrest	
state4.	The	importance	behind	studying	the	TRM9L	gene	is	that	the	evaluation	of	its	expression	
and	removal	from	the	cell	will	help	researchers	define	the	genetic	programs	associated	with	
aggressive	colorectal	cancer	cells,	which	may	promote	better	avenues	for	treatment.	
Colorectal	cancer	originates	in	the	epithelial	cells	of	the	colon	or	rectum	when	
mutations	occur	in	the	APC,	TP53,	and	TGFB	genes.	APC	(adenomatous	polyposis	coli)	gene	is	a	
tumor	suppressor	gene	that	prevents	the	buildup	of	β-catenin	protein.	Mutation	in	APC	leads	to	
an	accumulation	of	β-catenin	proteins	which	translocate	to	the	nucleus	and	bind	to	DNA	
activating	the	transcription	of	proto-oncogenes5.	Mutation	in	the	TP53	gene	produces	defective	
p53	proteins	responsible	for	controlling	cell	division	and	killing	cells	that	begin	to	divide	
rapidly6.	TGFB	is	responsible	for	producing	a	superfamily	of	proteins	that	regulate	growth	
inhibition	which	fails	after	a	mutation	in	the	gene.	TGFB	also	controls	a	portion	of	helper	T	cell	
differentiation	in	that	the	failure	of	proper	production	of	TGF-β1	proteins	inhibits	the	
differentiation	of	helper	T	cells,	making	the	cell	less	recognizable	by	the	body	as	hazardous7.	
Starting	in	the	mucosa	(inner)	layer	of	the	organ,	colorectal	cancer	progresses	through	
multiple	stages	begins	as	a	polyp	and	develops	into	a	metastasized	tumor.	The	advancement	of	
the	tumor	growth	is	depicted	below	in	Figure	2.		
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The	characteristics	of	each	stage	are	as	follows:	Stage	0	–	The	cancer	cells	begin	to	divide	in	the	
mucosa.	Stage	I	–	The	cells	invade	the	muscular	layer	of	the	colon/rectum	but	have	not	spread	
into	nearby	tissues/lymph	nodes.	Stage	II	–	Cancer	has	grown	through	the	wall	of	the	
colon/rectum	and	begun	to	spread	into	nearby	tissues,	but	not	to	the	lymph	nodes.	Stage	III	–	
Cells	are	now	spreading	into	nearby	lymph	nodes,	but	remain	localized	and	have	not	
disseminated	to	distant	regions	of	the	body.	Stage	IV	–	Cancer	is	now	metastasizing	into	
multiple	different	portions	of	the	body	making	treatment	exponentially	more	difficult8.	
Clustered	regularly	interspaced	short	palindromic	repeats	(CRISPR)	acts	as	an	immune	
system	for	prokaryotic	cells9.		CRISPR	acts	by	cutting	the	genetic	material	of	a	foreign	invader	
and	selectively	splicing	the	foreign	DNA	into	its	own	genome	for	future	reference	by	the	cell,	
Figure	2.	Progression	of	colorectal	cancer	from	Stage	0	to	Stage	IV.	
http://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/articles/health_tools/colorectal_cancer_slideshow/winslow_rm_illustration_of_colorectal_cancer_stages.jpg	
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working	as	an	immune	history/memory.	The	origin	of	CRISPR	began	with	Francisco	Mojica	in	
1993	when	his	group	identified	interrupted	repeats	of	DNA	in	the	genome	of	two	archaeal	
species	he	was	studying:	Haloferax	volcanii	and	Haloarcula	quadrata.	In	collaboration	with	
Ruud	Jansen,	Mojica	coined	the	term	CRISPR	in	one	of	Jansen’s	reports	in	2002	to	clear	the	
confusion	of	multiple	acronyms	circulating	at	the	time.	Mojica	began	to	identify	many	of	these	
interrupting	repeats	as	snippets	from	the	genomes	of	bacteriophages	leading	him	to	
hypothesize	that	CRISPR	is	an	adaptive	immune	system	for	prokaryotes.	Alexander	Bolotin	in	
2005	identified	Cas9	and	the	PAM,	protospacer	adjacent	motif,	sequence	when	studying	the	
bacteria	Streptococcus	thermophiles.		Dr.	Bolotin	noted	Cas9,	a	large	protein,	showed	nuclease	
activity,	and	that	many	of	the	spacers	shared	a	common	sequence	at	one	end	called	a	
protospacer	adjacent	motif	(PAM),	which	is	required	for	target	recognition.	In	2012,	Jennifer	
Doudna	and	Emmanuelle	Charpentier	reported	that	two	of	the	targeting	RNA	segments,	crRNA	
and	tracrRNA,	could	be	fused	together	to	create	one	single,	synthetic	guide	(known	as	gRNA)	
simplifying	the	CRISPR	system	drastically.	A	year	later,	Feng	Zhang	demonstrated	that	the	
CRISPR-Cas9	system	could	be	adopted	for	eukaryotic	organisms	as	they	successfully	performed	
genome	cleavage	in	human	and	mouse	models.	They	also	showed	that	the	system	could	drive	
homology-directed	repair	(HDR)	in	the	genome	which	is	important	for	gene	conversion,	and	
that	the	system	could	target	multiple	genomic	loci10.	Recently,	Cpf1	was	discovered	in	
Francisella	novicida	producing	a	new	system,	CRISPR-Cpf1	contrasted	to	CRISPR-Cas9,	which	
caused	a	staggered	cut	in	a	genome	as	compared	to	a	blunt	cut	produced	by	Cas9.		Also,	Cpf1	
only	requires	crRNA	inside	of	the	synthesized	gRNA	strand.	The	staggered	cut	is	important	as	it	
9	
	
makes	gene	conversion	much	simpler	and	smoother	for	a	cell	by	being	less	disruptive	to	the	
surrounding	genes11.	
Inside	the	CRISPR	complex,	gRNA	must	be	properly	formulated	to	target	the	correct	
region	of	genomic	DNA.	gRNA	consists	of	two	parts:	crRNA,	which	finds	the	desired	sequence,	
and	tracrRNA,	which	is	complementary	to	crRNA	so	it	combines	with	it	to	form	an	RNA	duplex	
and	turn	it	into	gRNA.	The	gRNA	goes	into	the	nucleus	of	a	cell	bound	to	the	Cas9	protein,	and	
will	bind	to	the	corresponding	DNA	sequence	so	that	Cas9	may	cleave	the	genome	at	the	PAM	
site,	which	is	a	2-6	base	pair	DNA	sequence	immediately	following	the	gRNA’s	target	sequence.	
PAM’s	characteristic	sequence	is	5’-NGG-3’,	where	N	is	any	nucleotide.	Different	Cas9	proteins	
have	different	PAM	sequences,	but	the	most	common	is	the	NGG	sequence	derived	from	
Streptococcus	pyogenes	bacteria12.		Once	cut,	the	open-ended	DNA	may	now	be	manipulated	to	
delete	a	certain	gene	or	insert	a	new	gene.	The	deletion	of	a	gene	occurs	when	the	cut	ends	are	
incorrectly	repaired	causing	an	indel	mutation,	thereby	inactivating	the	corresponding	protein	
once	translated.	To	achieve	a	deletion,	the	DNA	repair	pathway	needed	is	called	non-
homologous	end	joining	(NHEJ).		NHEJ	which	does	not	use	a	template	for	the	repair	process,	in	
contrast	to	homologous	directed	repair	(HDR)	which	does	use	a	parental	strand	as	a	template.		
NHEJ	will	remove	nucleotide	overhangs	near	the	cut	site	until	two	sufficient	blunt	ends	are	
achieved	with	the	ends	then	rejoined	through	DNA	ligation	which	leads	to	a	frameshift	
mutation.	Figure	3	is	a	schematic	detailing	how	the	CRISPR-Cas9	complex	interacts	with	the	
target	DNA	sequence	long	with	the	repair	process	the	cell	can	use	if	there	is	a	homologous	
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strand	of	DNA	in	the	nucleus	at	the	time	(HDR)	or	if	it	repairs	using	a	blunt	end	excision	
(NHEJ)13.	
	
A	CRISPR-Cas9	complex	seeks	target	strands	of	DNA	and	cleaves	at	the	desired	site	directed	by	
the	gRNA.	Once	used	to	eliminate	bacteriophages,	it	now	has	been	repurposed	to	selectively	
splice	in	and	out	genes	from	human	genomes.	Some	examples	of	this	include	the	generation	of	
transgenic	mice	by	the	disruption	of	five	genes:	Tet1,	2,	3,	Sry,	and	Uty14.		The	simplicity	of	
CRISPR	also	allows	for	a	new	form	of	gene	function	analysis	on	a	genome-wide	scale,	ultimately	
a	more	effective	version	of	genetic	screening15.		Duchenne	Muscular	Dystrophy,	what	was	once	
Figure	3.	Detailed	outline	of	CRISPR-Cas9	functioning	with	target	genome	and	the	cell	following	
HDR/NHEJ	repair.	
https://www.researchgate.net/profile/Xiangyu_Guo2/publication/280694279/figure/fig1/AS:281005891047431@1444008433288/Figure-1-CRISPR-
Cas9-targeting-system-In-the-CRISPRCas9-system-a-guide-RNA-hybridizes.png	
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a	severe	muscle-degenerative	disease	that	had	little	to	no	treatment	now	has	the	potential	for	
a	cure	by	means	of	an	exon	knock-in,	a	specialized	technique	that	is	only	capable	with	CRISPR16.		
The	goal	of	my	study	was	to	achieve	a	TRM9L	knockout	in	human	colorectal	cancer	cells	
(SW480)	using	CRISPR.		So	far,	we	have	successfully	generated	and	sequenced	the	required	
CRISPR	constructs	including	the	plasmid	that	contains	the	gRNA,	Cas9	gene,	and	GFP	gene.	The	
next	aim	is	to	culture	SW480	cells	and	add	these	constructs	to	observe	the	effects	of	a	TRM9L	
knockout.	Future	work	may	include	reorganizing	the	procedure	to	target	similar	but	different	
genes	in	the	genome	such	as	LIN9.	
	
	
Materials	and	Methods	
The	first	goal	of	my	work	was	to	identify	four	characteristic	DNA	sequences	in	the	
TRM9L	gene	for	targeting	by	CRISPR	gRNA.	This	initial	step	was	important	because	we	wanted	
to	select	sections	of	DNA	that	were	found	only	in	the	TRM9L	gene,	to	avoid	unwanted	off-target	
activity.	TRM9L	gene	exons	were	retrieved	from	NCBI	using	a	FASTA	sequence	download	of	the	
TRM9L	(KIAA1456)	gene	and	can	be	observed	below	in	Figure	4.		
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Random	20	base	pair	long	nucleotide	segments	beginning	with	ATG	(start	codon)	were	
identified	in	the	gene	and	analyzed	using	the	crispr.mit.edu	database.	We	chose	to	start	our	
nucleotide	analysis	with	ATG	because	an	ATG	sequence	indicated	the	start	of	a	new	open	
reading	frame,	therefore,	cutting	with	or	after	an	ATG	would	successfully	cut	out	a	section	of	a	
protein	from	an	exon.	The	crispr.mit.edu	database	compares	the	nucleotide	sequences	to	the	
rest	of	the	human	genome	to	determine	how	frequently	20	base-pair	(bp)	sections	of	those	
sequences	appeared	in	the	rest	of	the	genome.	The	sequences	were	then	given	a	score	from	0-
100	with	the	higher	the	score	meaning	the	less	often	it	was	found.	Sections	that	had	a	score	of	
over	85	(meaning	that	the	sequence	would	lead	to	very	few	off-target	interactions)	were	saved	
for	use	in	the	experiment.	An	example	of	this	is	shown	below	in	Figure	5.		
	
	
Figure	4.	The	FASTA	format	of	the	TRM9L	gene	which	contains	five	exons	and	four	introns.	
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For	each	20	bp	strand	selected,	the	5’-3’	complement	was	written,	and	then	rewrote	in	
reverse	as	each	strand	would	be	synthesized	in	the	5’-3’	fashion.	Eight	oligonucleotides	were	
developed,	four	selected	20	basepair	sequences	and	the	respective	four	reverse	compliment	
sequences,	with	the	eight	sequences	sent	to	Integrated	DNA	Technologies	(Coralville,	IA)	for	
chemical	synthesis	(Table	1).		
	
	
1	
	
Selected	
CAC	CGG	GGC	TCT	
GGA	CTA	GAC	TTT	C	
	
Score:	
85%	
	
	
Reverse	Compliment	
AAA	CGA	AAG	TCT	
AGT	CCA	GAG	CCC	C	
	
	
2	
	
Selected	
CAC	CGG	CGC	TGT	
GAC	TAC	TCG	CAA	C	
	
Score:	
95%		
Reverse	Compliment	
AAA	CGT	TGC	GAG	
TAG	TCA	CAG	CGC	C	
Figure	5.	Example	report	of	running	a	sequence	through	crispr.mit.edu	and	the	statistics	it	provides.	
(j)	
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3	
	
Selected	
CAC	CGG	CCA	ACT	
GAT	GAT	TTA	CGT	T	
	
Score:	
87%		
Reverse	Compliment	
AAA	CAA	CGT	AAA	
TCA	TCA	GTT	GGC	C	
	
	
4	
	
Selected	
CAC	CGG	TAG	GAA	
AAT	CGT	TTC	GTT	CC	
	
Score:	
88%		
Reverse	Compliment	
AAA	CGG	AAC	GAA	
ACG	AAT	TTC	CTA	CC	
Table	1.	Eight	oligonucleotide	sequences	sent	to	IDT	to	be	synthesized	5’-3’.	
	
The	oligonucleotides	needed	to	be	hybridized	and	cloned	into	a	destination	vector.		A	
plasmid	is	a	circular	piece	of	DNA	that	acts	as	a	vector.	A	plasmid	can	operate	independently	of	
the	genome	(i.e.,	autonomous	replication	and	segregation	into	dividing	cells),	but	is	also	able	to	
insert	and	combine	with	the	genome.	Plasmid	pX458	(Addgene,	Cambridge,	MA)	was	chosen	
for	its	successful	use	in	previous	experiments	by	Feng	Zhang’s	group,	and	because	it	contains	
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ampicillin	as	a	selectable	marker	in	E.	coli	and	offers	green	fluorescent	protein	(GFP)	for	
tracking	in	mamailian	cells17.		A	map	of	pX458	is	shown	in	Figure	6.		
To	start,	pX458	was	first	acquired	(through	lab	mentor	Khadijah	Onanuga)	and	digested.	
To	digest	the	plasmid,	1	µg	pX458	was	mixed	with	1	µL	FastDigest	BbsI	(Thermo,	Fredrick,	MD),	
1	µL	FastAP	(Thermo),	2	µL	10XFastDigest	Buffer,	and	enough	µL	of	ddH2O	to	produce	a	20	µL	
solution.	The	solution	was	then	placed	in	37°C	for	30	minutes.	A	0.8%	agarose	gel	was	prepared	
using	50	mL	of	TAE	buffer	(Tris	base,	Acetic	acid,	and	Ethylenediaminetetraacetic	acid)	and	0.4g	
of	agarose.	For	loading	the	lanes	in	the	gel,	Lane	1	contained	20µL	of	10kb	molecular	ladder,	
Lane	2	had	6µL	of	loading	dye	mixed	with	14µL	of	digested	plasmid	solution,	and	Lane	3	had	
6µL	of	loading	dye	with	the	remaining	plasmid	solution.	The	0.8%	gel	was	then	run	using	TAE	
buffer	and	1	µL	EtBr	for	1	hour	at	120V.	The	gel	was	placed	under	UV	light	and	small	cuts	were	
made	in	the	gel	to	excise	the	plasmid	DNA	in	Lanes	2	&	3	around	the	10kb	level	marked	by	the	
ladder	in	Lane	1.	
Figure	6.	Detailed	plasmid	pX458	gene	map	describing	different	primer/gene	regions.	
Image	retrieved	from	reference	(17)	
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Gel	extraction	was	performed	with	a	QIAquick	Gel	Extraction	kit	from	Qiagen18	
(Louisville,	KY),	according	to	the	supplier	protocol.	First,	the	gel	slices	were	weighed	in	a	micro-
centrifuge	tube	and	then	3x	the	volume	of	the	gel	was	added	in	Buffer	QG	(100mg	~	100µL).	
The	solution	was	incubated	at	50°C	for	10	minutes	with	periodized	vortexing	every	2-3	minutes.	
After	checking	to	reassure	that	the	color	of	the	mixture	is	yellow,	1	gel	volume	of	isopropanol	
was	added	to	the	mix.	The	mixture	was	applied	to	a	QIAquick	spin	column	in	a	2	mL	collection	
tube	and	then	centrifuged	for	1	minute	at	13,000	rpm.	The	flow	through	was	discarded	and	0.5	
mL	of	Buffer	QG	was	added.			The	sample	was	then	centrifuged	for	another	minute	and	0.75mL	
of	Buffer	PE	was	added	as	a	wash	and	then	the	tube	was	centrifuged	for	1	minute.	Lastly,	after	
the	flow-through	was	discarded,	the	spin	column	was	placed	in	a	new	micro-centrifuge	tube	
with	50	µL	of	Buffer	EB	added	to	the	center	of	the	column	and	centrifuged	for	one	last	minute.	
A	summary	of	DNA	gel	extraction	is	shown	in	Figure	7.	
	
	 The	oligonucleotides	were	re-suspended	in	a	solution	of	ddH2O	by	following	IDT’s	
Specification	Sheet	to	produce	a	final	concentration	of	100	µM.	The	oligonucleotides	were	
Figure	7.	DNA	in	agarose	bound	to	a	spin	column,	washed	with	multiple	buffers,	and	eluted.	
Image	retrieved	from	reference	(18)	
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phosphorylated	using	T4	polynucleotide	kinase	(T4	PNK)	in	the	following	recipe:	1	µL	of	Oligo	1	
(100	µM),	1	µL	of	Oligo	2	(100	µM),	1	µL	of	10X	T4	Ligation	Buffer	(NEB,	Ipswich,	MA),	6.5	µL	
ddH2O,	and	0.5	µL	of	T4	PNK	(NEB).	The	reaction	mixture	was	placed	in	a	thermocycler	for	
annealing:	37°C	for	30	minutes,	then	95°C	for	5	minutes	followed	by	ramping	down	to	25°C	at	
5°C/minute.	
	 To	insert	the	oligonucleotides	into	the	plasmid,	the	now	double-strand	oligo	sequences	
needed	to	be	ligated	into	the	plasmid	vector	using	DNA	Ligase.		The	ligation	reaction	was	
prepared	using	a	solution	of	50	ng	of	digested	pX458,	1	µL	oligonucleotide	duplex	in	a	1:250	
dilution,	5	µL	2X	QuickLigation	Buffer	(NEB,	Ipswich,	MA),	1	µL	of	Quick	Ligase	(NEB),	and	XµL	of	
ddH2O	which	produced	an	11µL	solution	that	then	sat	on	the	lab	bench	for	10	minutes.		
To	ensure	only	our	undigested,	ligated	plasmid	vectors	were	available	for	
transformation,	the	11	µL	from	the	ligation	reaction	was	mixed	with	1.5	µL	of	10X	PlasmidSafe	
buffer,	1.5	µL	10	mM	ATP,	1µL	PlasmidSafe	exonuclease	(Epicentre,	Madison,	WI).	The	reaction	
was	incubated	at	37°C	for	30	minutes,	then	70°C	for	30	minutes.	This	process	would	effectively	
remove	any	un-ligated/digested	plasmids	by	cleaving	individual	nucleotides	from	the	linear	
DNA	at	either	the	5’	and	3’	end.		Next,	the	remaining	circular	DNA	was	transformed	into	E.	coli.		
Epicentre’s	One	Shot	Stbl3	bacteria	were	cultured	in	One	Shot	vials	with	our	plasmids	according	
to	supplier	recommendations.	First,	the	One	Shot	vials	were	thawed	on	ice.	1-5	µL	of	plasmid	
DNA	was	added	to	the	vials	and	then	incubated	on	ice	for	30	minutes.	The	cells	were	heat	
shocked	for	45	seconds	at	42°C	and	then	placed	on	ice	for	2	minutes.	250	µL	of	S.O.C.	medium	
(Super	Optimal	Broth)	was	added	to	each	vial	and	then	shook	horizontally	for	1	hour	at	225	rpm	
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and	37°C.	25-100	µL	of	the	culture	from	each	vial	were	spread	out	on	100	µg/mL	LB	+	ampicillin	
plates	and	grown	overnight	at	37°C.		
To	ensure	the	characteristic	sequences	were	cloned	into	the	vectors,	plasmid	DNA	was	
sent	to	Genewiz	(South	Plainfield,	NJ)	for	DNA	sequencing.	To	prepare	the	plasmid,	three	
colonies	were	taken	from	each	plate	(grown	in	previous	section)	and	placed	into	5	mL	of	LB	+	
ampicillin	broth	producing	a	total	of	12	new	growth	solutions.	The	vials	were	left	to	grow	for	
approximately	16	hours	in	a	shaking	incubator.	The	solutions	were	centrifuged	at	13,500rpm	for	
10	minutes	at	4°C	and	then	decanted	leaving	the	cell	pellet	at	the	bottom.	We	then	used	a	
Qiagen	Plasmid	Extraction	kit	to	harvest	our	plasmid	from	the	bacteria	cells.		250	µL	of	p1	
buffer	was	pipetted	into	each	vial	to	resuspend	the	cells.	250	µL	of	p2	buffer	was	added	to	lyse	
the	cells.	P3	buffer	is	acidic	and	300	µL	of	p3	was	added	to	neutralize	the	basic	p2	buffer.	It	is	
important	to	note	that	p2	buffer	causes	the	solution	to	turn	blue	and	that	proper	incorporation	
of	p3	buffer	should	allow	the	solution	to	return	to	a	translucent	color.	After	the	inclusion	of	p3,	
bacterial	chromosomal	DNA	precipitates	out	leaving	this	fluffy	white	material	floating	in	
solution	as	seen	below	in	Figure	8.		
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The	vials	were	centrifuged	for	another	10	minutes	at	4°C	at	13,500	rpm.	The	liquid	was	pipetted	
out	from	each	vial	and	individually	applied	to	Qiagen	filter	columns	where	a	bind,	wash,	and	
elution	process	took	place.	The	vials	were	centrifuged	for	1	minute	at	4°C	and	13500	rpm	and	
flow-through	was	discarded.	750	µL	of	PE	buffer	was	used	to	wash	the	column,	spun	for	1	
minute,	and	flow-through	discarded.	The	tube	was	then	centrifuged	again	for	1	minute	and	the	
flow-through	was	discarded.	The	plasmid	DNA	was	eluted	with	45	µL	of	HyPure	warm	water	
into	a	new	Eppendorf	tube.	
A	sample	from	each	DNA	elution,	20µL,	was	taken	and	sent	to	GeneWiz	(South	
Plainfield,	NJ)	for	sequencing.	After	the	company	completed	the	sequencing	and	determined	
the	nucleotide	base	order	of	the	genetic	material	sent	to	them,	they	compiled	it	into	separate	
text	documents	and	sent	to	us.		We	used	the	text	files	to	evaluate	whether	our	plasmid	was	
inserted.	With	the	genetic	information	in	hand,	we	BLASTed	or	Aligned	the	genetic	sequence	
Figure	8.	Chromosomal	DNA	precipitating	out	of	solution	appearing	in	fluffy,	white	form.	
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with	our	original	pX458	plasmid.	In	this	comparative	process,	the	program	assesses	the	input	
DNA	and	compares	them	to	a	control	sequence	(the	original	plasmid)	to	find	regions	of	local	
similarity.	In	this	way,	the	program	can	align	small	portions	of	matching	genetic	information	to	
deliver	a	report	of	the	overall	alignment	and	matchup	of	the	two	genetic	sequences.	
Results	
To	first	ensure	the	initial	plasmid	sample	was	pure,	gel	electrophoresis	was	performed	
on	the	digested	pX458	solution	to	verify	plasmid	size	(Figure	9).		
	
	 A	single	band	resulted	at	the	expected	size	of	about	10	kb	as	the	band	is	approximated	
around	9.2	kb.	Using	a	gel	extraction	kit	allowed	us	to	purify	the	plasmid	band	from	the	gel.		
Figure	9.	Agarose	gel	analysis	of	digested	pX458	plasmid.	
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After	inclusion	of	the	plasmid	into	the	bacterial	One	Shot	Stbl3	E.	Coli	cultures	–	the	cells	
were	grown	and	spread	on	LB	+	ampicillin	plates.	Four	plates	grown	overnight	in	a	37°C	
incubator	(one	plate	for	each	respective	vector),	each	experimental	LB	+	Ampicillin	plate	
showed	colonygrowth	as	seen	in	Figure	10.	We	included	positive	and	negative	controls	during	
this	trial	to	ensure	it	was	our	plasmid	that	induced	the	results	by	having	one	plate	with	no	
streaked	bacteria,	and	one	plate	streaked	with	bacteria	that	had	not	been	exposed	to	our	
recombinant	vector.	No	colonies	grew	on	either	control	plate	(data	not	shown).	
	
After	the	Plasmid	Purification	step,	the	concentration	of	DNA	in	each	vial	was	tested	to	
ensure	the	DNA	had	been	successfully	harvested	from	cells	and	was	now	in	solution.	A	
NanoDrop	Spectrophotometer	was	used	to	measure	the	DNA	concentration	in	ng/µL	by	placing	
Figure	10.	Four	LB	+	Amp	plates	that	contained	Stbl3	cultures	transfected	with	
respective	recombinant	pX458	plasmids.	
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a	single	microliter	of	sample	on	the	spectrophotometer	and	having	the	program	run	the	test	
under	‘Nucleic	Acids’.	Nanodrop	concentration	data	is	shown	in	Table	2.	
Sample#	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	 11	 12	
DNA	[]	 149.7	 225.6	 147.9	 131.8	 161.0	 156.8	 129.7	 148.9	 151.8	 152.9	 126.9	 123.3	
Table	2.	Concentration	of	DNA	in	ng	ng/µL	corresponding	to	its	sample	number.	
I	was	able	to	take	the	results	I	received	from	GeneWiz	and	use	an	Alignment	tool	to	
compare	the	original	pX458	vector	with	genetic	sequence	of	the	recombinant	vector.	The	
Alignment	tool	lays	out	in	order	each	respective	genetic	sequence	5’-3’	and	then	determines	
the	number	of	mismatch	base	pairs	(where	the	nucleotides	in	different	pieces	of	DNA	are	not	
the	same),	and	calculates	the	percentage	of	mismatches	after	accounting	for	frameshifts	that	
may	occur	due	to	the	mismatches.	An	alignment	score	under	100%	indicates	there	were	
modifications	made	to	the	genetic	sequence	of	the	plasmid,	and	after	checking	with	the	
mismatches	with	our	oligonucleotide	sequences	–	it	can	be	determined	that	those	base	pair	
differences	can	be	attributed	to	the	inclusion	of	the	desired	oligonucleotides	(Figure	11).		
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Discussion	
Overall,	the	effectiveness	of	the	CRISPR	technique	is	unable	to	be	determined	as	the	
concluding	portions	of	the	experiment	have	yet	to	be	undertaken.	CRISPR	is	regarded	as	a	
precise	technique	that	can	specifically	alter	the	genome	of	a	desired	organism	with	few	
undesirable	interactions,	and	so	this	hypothesis	is	sought	to	be	evaluated	in	the	coming	term.		
Should	CRISPR	not	operate	as	expected	in	the	experiment,	there	are	other	techniques	that	
produce	a	similar	outcome	such	as	RNAi	(RNA	interference)	which	are	essentially	RNA	strands	
that	target	and	neutralize	mRNA	strands	preventing	gene	translation	after	transcription13.	RNAi	
would	be	capable	of	negatively	manipulating	(aka	deletion/prevention)	TRM9L	expression	
comparable	to	the	outcome	of	CRISPR,	making	it	a	plausible	alternative	technique.	
Figure	11.	Snapshot	of	recombinant	plasmid	alignment	data	in	comparison	to	the	normal	pX458	vector	
with	the	yellow	highlight	indiciating	the	original	sequence	of	the	plasmid	and	the	green	highlight	after	
editing	and	including	the	oligonucleotides.	
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Pitfalls	and	Limitations	
	 Completing	these	experiments	was	a	great	learning	experience	not	just	because	of	the	
novel	techniques	and	new	procedures,	but	also	because	it	exposed	many	things	I	had	not	been	
conscience	about.	For	example,	it	was	not	clear	in	the	first	steps	of	digestion	which	buffer	to	
use	because	the	recipe	called	for	a	different	medium	than	what	was	in	stock.	Knowing	one	of	
the	available	buffers	was	an	appropriate	substitution,	I	took	the	one	that	seemed	most	likely	
correct	instead	of	seeking	scientific	clarification.	A	buffer	lacking	BSA	was	chosen	when	a	buffer	
with	BSA	was	required	holding	the	experiment	back	an	interval	of	time	due	to	the	incorrect	
usage	of	a	buffer.	
	 A	simple	misunderstanding	that	spiraled	into	a	semester	long	conundrum	was	the	
difference	between	agar	and	agarose.	Knowing	one	is	used	to	make	plates	and	one	is	used	to	
make	gels	is	common	knowledge,	however,	I	failed	to	realize	there	was	a	significant	difference	
between	the	two	and	that	the	selection	of	the	ingredient	would	effectively	alter	the	entire	
efficacy	of	the	experiment.	I	had	chosen	wrong	for	multiple	months.	
	 The	last	issue	to	touch	on	is	the	expectation	of	time	in	the	laboratory.	Simple	logic	could	
help	generate	a	time	table	for	many	of	the	experiments	and	procedures	that	will	be	
undertaken,	however,	doing	so	lends	a	serious	underestimation	of	experiment	success	rates	
and	reagent	reliability	–	especially	for	the	first	time	running	through	a	new	procedure.	I	could	
often	guess	how	long	I	should	be	in	lab	for	any	given	portion	of	the	experiment,	but	I	constantly	
failed	to	take	into	consideration	what	it	might	mean	to	my	plan	should	a	portion	of	my	
experiment	fail	or	I	did	not	have	the	proper	reagents	available	to	me.	Doing	so	held	back	my	
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progress	for	quite	a	bit	of	time	which	is	why	I	learned	it	is	important	to	give	amble	time	to	both	
the	procedures	and	the	overall	progress	of	the	experiment.	
Current	Work	in	the	Field	
	 CRISPR	is	a	popular	topic	in	biomedical	research	currently	due	to	its	recent	discovery	
and	the	DNA	editing	potential	that	it	offers.	Many	groups	are	pioneering	work	in	this	field,	such	
as	the	Rotello	group	at	the	University	of	Massachusetts.	The	Rotello	group	wanted	to	focus	on	
how	to	improve	actual	CRISPR-Cas9	entry	into	the	nucleus.		Currently	there	are	few	effective	
methods	that	will	successfully	transfer	the	complex	into	the	cytosol	and	then	into	the	nucleus	
as	well	without	being	degraded.	The	Rotello	group	achieved	a	highly	efficient	translocation	of	
CRISPR-Cas9	by	coupling	a	complexed	Cas9	(had	a	gRNA	bound	to	it)	with	carrier	gold	
nanoparticles	to	generate	nanoassemblies.	This	method	allowed	for	a	90%	delivery	rate	of	Cas9	
proteins	into	the	nucleus	and	is	important	because	it	offers	a	new,	effective	method	to	
efficiently	transport	Cas9	complexes	into	the	nucleus	without	experiencing	degradation.	The	
new	approach	opens	possibilities	into	studying	genome	dynamics	and	more	effective	CRISPR	
treatments	in	eukaryotic	organisms20.	
	 The	Ohta	group	used	the	CRISPR-Cas9	system	to	better	explore	colorectal	cancer	by	
selectively	causing	mutations	and	deletions	in	known	hallmark	genes.	The	group	was	
attempting	to	explore	the	extent	to	which	each	genes	pathology	contributed	to	the	
development	of	colorectal	cancer	when	mutated	by	individually	targeting	each	gene.	This	work	
is	important	because	they	are	offering	new	information	on	which	genes	are	critical	in	colorectal	
carcinogenesis,	which	yields	more	descriptive	information	for	researchers	attempting	to	
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discover	cures	or	treatments	for	this	type	of	cancer,	by	informing	them	which	genes	are	worth	
focusing	on.	The	Ohta	group	showed	that	mutations	in	the	tumor	suppressor	genes	APC,	
SMAD4,	and	TP53	formed	tumors	after	implantation,	but	these	cells	require	additional	
molecular	lesions	to	exhibit	more	invasive	behavior21.	
	 When	devising	a	CRISPR-mediated	experiment,	it	is	important	to	determine	the	
expected	efficiency	of	the	CRISPR-Cas9	model	with	the	targeted	genetic	site	to	evaluate	
whether	the	model	can	be	predicted	to	work	as	intended.	The	Liu	group	in	Harvard	successfully	
derived	a	new	sequence	model	which	predicts	gRNA	efficiency	in	CRISPR-Cas9	knockout	
experiments.	They	assessed	the	DNA	sequence	features	which	contribute	to	gRNA	efficacy	over	
multiple	designs	to	discover	new	features	indicative	of	efficiency	such	as	a	preference	for	
cytosine	at	the	cleavage	site.	Their	work	helps	improve	others	CRISPR	research	because	it	
allows	researchers	to	now	better	determine	their	chance	of	a	successful	completion	of	their	
experiment	based	on	their	designed	CRISPR	model22.	
	 CRISPR-Cas9	systems	have	been	more	popular	in	cancer	research	as	of	late,	as	scientists	
attempt	to	narrow	down	and	interact	with	specific	genes	and	encoding	exons,	to	evaluate	the	
protein’s	relationship	with	cancer	development.	The	Vakoc	group	focused	CRISPR-Cas9	
mutagenesis	on	exons	encoding	functional	protein	domains	which	lead	to	a	higher	proportion	
of	null	mutations,	and	had	substantially	increased	the	potency	of	negative	selection	during	
cellular	assays.	Their	work	provides	a	replicable	process	to	carry	out	the	same	type	of	analysis	
on	the	identification	of	protein	domains	that	sustain	cancer	cells	and	which	are	suitable	for	
drug	targeting23.	
27	
	
	 While	CRISPR	research	is	becoming	highly	prevalent,	the	practice	is	still	currently	
constrained	by	the	need	of	a	specific	PAM	sequence	for	the	CRISPR-Cas9	nuclease	function	to	
operate	correctly.	The	Zheng	group	sought	to	address	this	very	problem,	and	successfully	
showed	that	the	commonly	used	Cas9	protein	(SpCas9	from	Streptococcus	pyogenes)	can	be	
modified	to	recognize	alternative	PAM	sequences	by	altering	the	evolution	of	the	bacterium.	
Their	work	increases	the	ease	of	use	and	functionality	of	many	other	experiments	by	making	
CRISPR	targeting	easier	and	more	specific.	They	proved	the	efficacy	of	the	new	altered	PAM	
sequences	by	editing	hard	to	target	endogenous	gene	sites	in	both	zebrafish	and	human	cells,	
sites	which	were	not	targetable	by	SpCas924.	
	 Genetic	screens	are	considered	one	of	the	best	tools	for	identifying	genes	that	are	
responsible	for	diverse	phenotypes	in	expressing	organisms.	Researchers	conducted	a	genome-
wide	CRISPR/Cas9-mediated	loss-of-function	screen	in	tumor	growth	and	metastasis	in	mice.	
After	mutagenizing	a	non-metastatic	mouse	cancer	cell	line	with	a	genome-scale	library	of	
gRNAs,	they	showed	that	the	mutant	cell	pool	rapidly	generated	metastasized	tumors	when	
transplanted	into	mice.	The	developed	screening	method	revealed	genes	regulating	lung	
metastasis	in	mice,	and	highlighted		the	use	of	Cas9-based	screening	as	an	effective	method	to	
systematically	assay	gene	phenotypes	in	the	evolution	of	cancer25.	
	 Editing	other	organisms’	DNA	could	be	beneficial	to	humans	by	reducing	the	negative	
impact	these	organisms	can	have	on	our	environment.	Editing	approaches	could	range	from	
antimicrobial-resistant	bacteria,	to	the	reduction	of	virus-spreading	insects.	The	Nolan	group	of	
researchers	experimented	with	a	CRISPR-Cas9	treatment	and	Anopheles	gambiae	(mosquito	
species)	to	target	gene	drive	systems	to	reduce	these	insects’	ability	to	spread	malaria.	After	
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identifying	three	separate	genes,	they	showed	the	CRISPR-Cas9	disruption	to	the	gene	loci	had	
a	transmission	rate	to	progeny	at	about	91.4-99.6%.	Their	findings	conclude	that	targeting	just	
one	loci	meets	the	minimum	requirement	for	a	gene	drive	targeting	female	reproduction	in	the	
insect	population	to	propagate,	showing	that	further	research	into	the	topic	could	severely	
reduce	and	suppress	mosquito	populations	ceasing	the	transmission	of	malaria26.		
	 While	many	researchers	are	making	CRISPR	more	efficient	and	easily	practicable,	there	
are	also	many	researchers	focusing	on	reducing	the	negative	side	effects	of	a	CRISPR	
experiment.	The	Joung	group	is	focusing	on	reducing	off-target	effects	that	results	when	a	Cas9	
protein	reacts	to	more	DNA	sequences	than	intended.	By	modifying	the	SpCas9	protein	to	
generate	SpCas9-HF1,	a	high-fidelity	variant,	the	function	of	the	new	protein	retained	all	on-
target	activities	comparable	to	wild-type	SpCas9	with	over	85%	of	sgRNAs,	however,	all	typical	
off-target	events	or	interactions	were	nonexistent	or	undetectable.	Research	like	this	increases	
the	potential	efficacy	and	plausibility	of	future	CRISPR-Cas9	therapy	treatments	by	increasing	
the	specificity	and	accuracy	of	the	treatment	as	they	decrease	the	chances	of	an	adverse	
reaction	with	the	DNA27.	
	 Further	increasing	the	efficacy	of	potential	CRISPR	therapeutic	treatments,	the	
Anderson	group	experimented	with	delivery	methods	of	CRISPR-Cas9	systems	to	target	cells	to	
try	improving	the	bioavailability	of	these	treatments.	They	generated	a	new	delivery	system	by	
combining	lipid	nanoparticle-mediated	delivery	of	the	Cas9	mRNA	and	gRNA	along	with	a	repair	
template	with	adeno-associated	viruses	as	they	evaluated	the	ability	for	these	injections	to	
treat	and	repair	diseased	genes	in	adult	mice.	They	showed	a	correction	efficiency	of	over	6%	
when	targeting	a	mouse	model	with	human	hereditary	tyrosinemia.			A	single	application	to	the	
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mice	generated	fumarylacetoacetate	hydrolase	(Fah)-positive	hepatocytes	by	correcting	the	
causative	Fah-splicing	mutation.	Their	findings	increase	the	potential	utility	of	therapeutic	Cas9-
based	genome	editing	for	a	variety	of	DNA-based	diseases28.	
	 The	end	goal	of	most	CRISPR	research	is	to	improve	or	understand	more	about	the	
CRISPR	process	so	that	it	can	be	used	as	a	therapeutic	treatment	in	humans.	The	Liu	group	
recently	published	a	paper	where	they	tried	first-hand	repairing	genetic	abnormalities	in	a	
single-cell	embryo	to	attempt	for	one	of	the	first	time	‘designer	babies’.	The	disease	they	were	
attempting	to	treat	was	a	mutation	called	G1376T	in	the	G6PD	enzyme	which	commonly	causes	
favism,	a	disorder	where	eating	certain	foods	such	as	fava	beans	can	cause	the	destruction	of	
red	blood	cells.	Their	method	was	to	use	CRISPR	to	cut	out	the	mutated	genes	while	also	
splicing	in	the	correct	genetic	sequence.	While	their	success	rate	was	low	in	repairing	these	
mutations,	a	rate	less	than	1	in	10,	it	is	still	encouraging	to	receive	results	showing	that	the	
treatment	may	be	capable	with	more	research	and	development29.	
Conclusions	
	 In	conclusion	of	the	work,	it	can	be	deemed	that	the	pX458	plasmid	was	successfully	
engineered	to	include	the	targeting	double	stranded	DNA	specific	to	the	hTRM9L	gene	in	
SW480	cells.	The	experiment	has	been	halted	at	the	characterization	step	after	the	SW480	cells	
were	transfected	with	the	recombinant	pX458	plasmid,	verified	through	GFP	bioluminesnce.	
Future	Plans	
	 The	next	steps	after	the	transfection	of	the	SW480	cells	using	an	EZ480	transfection	
reagent	via	a	normal	transfection	protocol,	we	will	grow	a	separate	culture	of	SW480	cells	to	
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use	as	a	control	for	the	experiment,	and	then	use	GFP	luminescence	to	evaluate	the	degree	of	
plasmid	inclusion	by	the	cells	as	GFP	was	included	in	the	pX458	plasmid,	and	we	can	sort	the	
GFP	expressing	cells	by	fluorescence	activated	cell	sorting	(FACS).	To	determine	the	effect	of	
TRM9L	deletion,	we	will	carry	out	live-dead	assays	with	trypan	blue	staining	and	then	contrast	
the	growth	of	the	edited	SW480	cells	with	the	control	SW480	cells.	After	observing	the	effects	
of	eliminating	TRM9L	from	colorectal	cancer	cells,	it	might	prove	interesting	to	try	modifying	
the	procedure	to	insert	more	copies	of	TRM9L	into	the	genome.	By	increasing	the	
concentration	of	TRM9L	in	the	genome,	the	cancer	cells	may	be	less	able	to	downregulate	
these	genes	allowing	for	some	transcription,	and	since	TRM9L	is	a	tumor	suppression	gene,	
possibly	halt	the	growth	of	these	cancer	cells.	
	 TRM9L	is	one	of	many	genes	of	interest	in	the	genome	that	relate	to	cancer	growth.	By	
utilizing	the	same	principles	implemented	in	this	experiment,	the	target	could	be	replaced	to	
observe	the	effects	of	the	elimination	of	another	gene.	A	few	examples	include	targeting	LIN9,	
the	tumor	suppression	gene	that	TRM9L	directly	upregulates	when	expressed,	and	observe	the	
effects	of	when	this	gene	is	knocked	out	from	the	cell.	Another	is	the	APC	gene	which	is	also	
classified	as	a	tumor	suppressor	gene	due	to	its	function	in	controlling	how	often	a	cell	divides,	
how	it	attaches	to	other	cells,	and	how	a	cell	moves	within	a	tissue30.	The	MLH1	gene	codes	for	
a	DNA	mismatch	repair	protein,	a	gene	where	should	a	mutation	occur,	often	does	lead	to	
colon	cancer.	Lastly,	the	TGFBR2	gene	codes	for	a	cell	membrane	receptor	responsible	for	signal	
transduction	that	may	also	lead	to	colorectal	cancer	should	a	mutation	occur	as	the	gene	plays	
a	role	in	regulating	cell	division31.	
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